Management of Renal Disease

  • Author: Mohamed G. Atta, MD, MPH (More Info)
  • Editors in Chief: Daniel R. Kuritzkes, MD; Joseph J. Eron, Jr., MD
  • Last Reviewed: 3/14/17 (What's New)

Summary

  • Equal and additive risk of morbidity and mortality that proteinuria signals is separate and distinct from risk identified by lesser eGFR (Figure 3)[KDIGO]
    • Underscores use of screening for and treating proteinuria regardless of GFR
  • After starting treatment, proteinuria level should be reassessed every 3 months until goal has been achieved

Action required

Keywords: Cardiovascular Disease, Renal Complications

©2020 Clinical Care Options, LLC. All Rights Reserved.

The materials published via inPractice® reflect the views of the reviewers or authors of the material, not those of Clinical Care Options, LLC, the accredited provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.